{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T13:37:10Z","timestamp":1761917830894,"version":"3.44.0"},"reference-count":18,"publisher":"BMJ","issue":"5","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["DTB"],"published-print":{"date-parts":[[2016,5]]},"abstract":"<jats:p>Midodrine (Bramox\u2014Brancaster Pharma Limited) was authorised in the UK by the Medicines and Healthcare products Regulatory Agency (MHRA) in March 2015 for \u201cthe treatment of severe orthostatic hypotension due to autonomic dysfunction in adults when corrective factors have been ruled out and other forms of treatment are inadequate\u201d.<jats:sup>1<\/jats:sup> Previously, midodrine had only been available in the UK as an unlicensed product used on a named-patient basis. It is the first drug to be licensed in the UK for the treatment of orthostatic hypotension. Here we consider the evidence for midodrine in the treatment of severe orthostatic hypotension and how it fits with current management strategies.<\/jats:p>","DOI":"10.1136\/dtb.2016.5.0399","type":"journal-article","created":{"date-parts":[[2016,5,12]],"date-time":"2016-05-12T10:12:56Z","timestamp":1463047976000},"page":"54-56","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":7,"title":["Midodrine for severe orthostatic hypotension"],"prefix":"10.1136","volume":"54","member":"239","published-online":{"date-parts":[[2016,5,12]]},"reference":[{"key":"2025082623220443000_54.5.54.1","unstructured":"Bramox 2.5 and 5mg tablets. Summary of product characteristics, UK. Brancaster Pharma Limited, March 2015."},{"key":"2025082623220443000_54.5.54.2","doi-asserted-by":"publisher","DOI":"10.1007\/s10286-011-0119-5"},{"key":"2025082623220443000_54.5.54.3","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1331.2006.01512.x"},{"key":"2025082623220443000_54.5.54.4","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1111\/joim.12021","article-title":"Syndromes of orthostatic intolerance: a hidden danger","volume":"273","author":"Federowski","year":"2012","journal-title":"J Int Med"},{"key":"2025082623220443000_54.5.54.5","doi-asserted-by":"publisher","DOI":"10.2165\/00002512-200926050-00002"},{"key":"2025082623220443000_54.5.54.6","doi-asserted-by":"crossref","unstructured":"Lahrmann H , et al . Orthostatic hypotension. In: Gilhus NE (Eds), et al . European Handbook of Neurological Management. Second Edition. Oxford: Wiley, 2011.","DOI":"10.1002\/9781444328394.ch33"},{"key":"2025082623220443000_54.5.54.7","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehp298"},{"key":"2025082623220443000_54.5.54.8","doi-asserted-by":"publisher","DOI":"10.1093\/ageing\/afs061"},{"key":"2025082623220443000_54.5.54.9","unstructured":"Health and Social Care Information Centre, 2016. Prescription Cost Analysis England 2015 [online]. Available: http:\/\/www.hscic.gov.uk\/catalogue\/PUB20200\/pres-cost-anal-eng-2015-rep.pdf [Accessed 20 April 2016]."},{"key":"2025082623220443000_54.5.54.10","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-013-2520-3"},{"key":"2025082623220443000_54.5.54.11","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000000815"},{"key":"2025082623220443000_54.5.54.12","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1007\/s11606-014-3014-7","article-title":"Midodrine efficacy in orthostatic hypotension","volume":"29","author":"Singer","year":"2014","journal-title":"J Gen Intern Med"},{"key":"2025082623220443000_54.5.54.13","doi-asserted-by":"publisher","DOI":"10.1111\/ijcp.12122"},{"key":"2025082623220443000_54.5.54.14","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(93)90230-M"},{"key":"2025082623220443000_54.5.54.15","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1997.03540370036033"},{"key":"2025082623220443000_54.5.54.16","unstructured":"Scottish Medicines Consortium, 2015. Midodrine hydrochloride (Bramox) [online]. Available: https:\/\/www.scottishmedicines.org.uk\/SMC_Advice\/Advice\/1094_15_midodrine_hydrochloride_Bramox\/midodrine_hydrochloride_Bramox [Accessed 20 April 2016]."},{"key":"2025082623220443000_54.5.54.17","unstructured":"All Wales Medicines Strategy Group, 2015. Midodrine hydrochloride (Bramox) [online]. Available: http:\/\/www.awmsg.org\/awmsgonline\/app\/appraisalinfo\/2650 [Accessed 20 April 2016]."},{"key":"2025082623220443000_54.5.54.18","unstructured":"National Institute for Health and Care Excellence, 2015. Orthostatic hypotension due to autonomic dysfunction: midrodine [online]. Available: https:\/\/www.nice.org.uk\/advice\/esnm61\/resources\/orthostatic-hypotension-due-to-autonomic-dysfunction-midodrine-1502681100183493 [Accessed 20 April 2016]."}],"container-title":["Drug and Therapeutics Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/dtb.2016.5.0399","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T06:22:18Z","timestamp":1756275738000},"score":1,"resource":{"primary":{"URL":"https:\/\/dtb.bmj.com\/lookup\/doi\/10.1136\/dtb.2016.5.0399"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5]]},"references-count":18,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2016,5,12]]},"published-print":{"date-parts":[[2016,5]]}},"alternative-id":["10.1136\/dtb.2016.5.0399"],"URL":"https:\/\/doi.org\/10.1136\/dtb.2016.5.0399","relation":{},"ISSN":["0012-6543","1755-5248"],"issn-type":[{"type":"print","value":"0012-6543"},{"type":"electronic","value":"1755-5248"}],"subject":[],"published":{"date-parts":[[2016,5]]}}}